Form 4: Contineum CSO Sells Shares Under Pre-Arranged Plan

Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 4,170 shares of Class A Common Stock in pre-arranged transactions.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), sold a total of 4,170 shares of Class A Common Stock.
• The sales occurred on February 3, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
• One transaction involved the sale of 3,000 shares at a weighted average price of $14.8229 per share, with prices ranging from $14.12 to $15.08.
• A second transaction involved the sale of 1,170 shares at a weighted average price of $15.2451 per share, with prices ranging from $15.12 to $15.45.
• Following these transactions, Daniel S. Lorrain directly beneficially owns 156,052 shares of Class A Common Stock.
• An additional 6,842 shares are indirectly beneficially owned by a spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development. While insider selling typically carries a negative connotation, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on new, non-public information.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, which indicates the sales were pre-scheduled and not based on new, non-public information, reducing concerns about opportunistic insider selling.

Negatives

• The Chief Scientific Officer reduced their direct beneficial ownership by 4,170 shares, which could be interpreted by some investors as a slight reduction in insider conviction, despite the 10b5-1 plan.

Risks

• Market perception of insider selling, even when pre-planned, can sometimes lead to negative sentiment or short-term price volatility.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries, including biotechnology. These plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information. While the sale itself is a reduction in insider holdings, the pre-planned nature often mitigates concerns that might arise from discretionary sales.

Related Party Transactions

• The sale of Class A Common Stock by Daniel S. Lorrain, the Chief Scientific Officer, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the reduction in direct insider ownership differently, though the 10b5-1 plan suggests a lack of new, negative information influencing the sale.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider stock sale under a 10b5-1 plan. Such transactions are generally not indicative of a significant change in company fundamentals or management's long-term outlook. Therefore, a seasoned investor would likely maintain their current position, awaiting more substantive financial or operational updates before adjusting their investment thesis.

Keywords

Contineum Therapeutics, CTNM, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Chief Scientific Officer, Daniel S. Lorrain, Biotechnology, Pharmaceuticals